Tradestie Institutional Equity Comparison Engine

KTTA vs SRZN โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-20 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

SRZN Overall Edge

SRZN Captures Institutional Edge (2โ€“1 Pillars ยท 4โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Momentum & Technical, Options & Structure while KTTA counters with relative strength in Growth & Margin. Fundamentally, KTTA trades at N/M Forward P/E with 0.0% operating margin (+1498.1% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, KTTA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
KTTA N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner KTTA
Op Margin 0.0% vs -485.4% ยท YoY +1498.1% vs +408.6%
Momentum & Technical Winner SRZN
1Y +0.6% vs +110.8% ยท 52W Pos 11% vs 63%
Options & Structure Winner SRZN
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (13th %ile IV)
KTTA NASDAQ
Pasithea Therapeutics Corp. Common Stock
Pharmaceutical Preparations
$0.48
-0.48% 1D
Market Cap $17.7M
1M Return +7.52%
1Y Return +0.59%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 20.0 Fund 40.0 Flow 50.0 Mom 60.0
SRZN NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$28.46
-7.21% 1D
Market Cap $642.7M
1M Return +10.52%
1Y Return +110.81%
Forward P/E N/M
Unified AI Score
36.0 / 100 SELL
Tech 15.0 Fund 42.0 Flow 65.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: KTTA +0.59% SRZN +110.81% Spread: +110.22 pp (SRZN Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period KTTA Revenue SRZN Revenue KTTA Op. Margin SRZN Op. Margin Margin Edge
FY2021 $0M N/A -29925.7% N/A KTTA
FY2022 $0M $10M -2587.3% -354.7% SRZN
FY2024 N/A $10M N/A -239.7% SRZN
FY2025 N/A $0M N/A -1210.6% SRZN

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: KTTA (3) vs SRZN (4)
Institutional Metric KTTA SRZN Criterion Row Winner
Market Capitalization Scale $17.7M $642.7M Larger Scale SRZN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +1498.1% +408.6% Higher Growth KTTA
Operating Margin (TTM) Profitability 0.0% -485.4% Higher Margin KTTA
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -88.8% -62.8% Higher ROE SRZN
52-Week Range Position Momentum 11% ($0โ€“$2) 63% ($13โ€“$38) Stronger Trend SRZN
Beta / 30D Volatility Risk Regime 0.68ฮฒ ยท 185% Vol 1.29ฮฒ ยท 73% Vol Lower Realized Risk SRZN
Unified Institutional Score Composite Signal 42.1 / 100 (HOLD) 36.0 / 100 (SELL) Higher Composite KTTA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full KTTA vs SRZN Buy Guide
KTTA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live KTTA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SRZN CONSOLIDATION
41d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live SRZN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither KTTA nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.